<?xml-stylesheet type="text/css" href="C:\Users\Fernando\Documents\CIPF\Pharm Pract\Pubmed Central\JATS_OXYGEN\jats.css"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharm Pract (Granada)</journal-id><journal-id journal-id-type="iso-abbrev">Pharm Pract (Granada)</journal-id><journal-id journal-id-type="publisher-id">Pharm Pract</journal-id><journal-title-group><journal-title>Pharmacy Practice</journal-title></journal-title-group><issn pub-type="ppub">1885-642X</issn><issn pub-type="epub">1886-3655</issn><publisher><publisher-name>Centro de Investigaciones y Publicaciones Farmaceuticas</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25147590</article-id><article-id pub-id-type="pmc">4139754</article-id><article-id pub-id-type="publisher-id">PhP-224</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Relationship between drug interactions and drug-related negative clinical outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cremades</surname><given-names>Javier</given-names></name><aff>Community Pharmacists at Aspe, Alicante (<country>Spain</country>).</aff></contrib><contrib contrib-type="author"><name><surname>Gonzalo</surname><given-names>Mario</given-names></name><aff>Community Pharmacist at Crevillente, Alicante (<country>Spain</country>)</aff></contrib><contrib contrib-type="author"><name><surname>Arrebola</surname><given-names>Isabel</given-names></name><aff>Community Pharmacists at Aspe, Alicante (<country>Spain</country>)</aff></contrib></contrib-group><pub-date pub-type="ppub" iso-8601-date="20130331"><season>Jan-Mar</season><year iso-8601-date="2012">2009</year></pub-date><pub-date pub-type="epub" iso-8601-date="20130328"><day>15</day><month>3</month><year iso-8601-date="2012">2009</year></pub-date><volume>7</volume><issue>1</issue><fpage>34</fpage><lpage>39</lpage><history><date date-type="received"><day>23</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pharmacy Practice</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Drug interactions may represent an iatrogenic risk that should be controlled in community pharmacies at the dispensing level.</p><sec sec-type="aim"><title>Aim</title><p>We analyzed the association between potential drug-drug interactions (DDIs) and negative clinical outcomes.</p></sec><sec sec-type="methods"><title>Methods</title><p>We used dispensing data from two community pharmacies: instances where drug dispensing was associated with a potential DDI and a comparison group of randomized dispensing operations with no potential DDI. In cases where potential DDIs were detected, we analyzed the underlying negative clinical outcomes. Age and gender data were included in the analysis.</p></sec><sec sec-type="results"><title>Results</title><p>During the study period, we registered 417 potential DDIs. The proportion of women and age were higher in the study group than in the comparison group. The average potential DDIs per patient was 1.31 (SD=0.72). The Consejo General de Colegios Oficiales de Farmac&#x000e9;uticos (CGCOF) database did not produce an alert in 2.4% of the cases. Over-the-counter medication use was observed in 5% of the potential DDI cases. The drugs most frequently involved in potential DDIs were acenocoumarol, calcium salts, hydrochlorothiazide, and alendronic acid, whereas the most predominant potential DDIs were calcium salts and bisphosphonates, oral antidiabetics and thiazide diuretics, antidiabetics and glucose, and oral anticoagulant and paracetamol. The existence of a drug-related negative clinical outcome was observed only in 0.96% of the potential DDI cases (50% safety cases and 50% effectiveness cases).</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Only a small proportion of the detected potential DDIs lead to medication negative outcomes. Considering the drug-related negative clinical outcomes encountered, tighter control would be recommended in potential DDIs with NSAIDs or benzodiazepines.</p></sec></abstract><kwd-group kwd-group-type="MESH"><kwd>Drug Interactions</kwd><kwd>Community Pharmacy Services</kwd><kwd>Spain</kwd></kwd-group></article-meta></front><body><sec id="S1"><title>INTRODUCTION</title><p>A drug interaction is defined as the alteration of the effect of one drug by the presence of another. The number of drug interactions increases with to the number of drugs used. Because increased life expectancy is accompanied by an increase in medication use, this field of pharmacotherapy is an important public health issue.<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref></p><p>The incidence of drug interactions is a controversial issue. Study results vary greatly because of population type and methodology. Apart from this complexity, we must distinguish between potential drug-drug interactions (potential DDI) and drug-drug interactions that actually occur.<xref rid="B2" ref-type="bibr">2</xref></p><p>The frequency of potentially dangerous interactions in ambulatory patients is genuinely low.<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref> However, if we take into account the large number of drugs that are prescribed and dispensed on a daily basis, a considerable number of patients can potentially be at risk.<xref rid="B2" ref-type="bibr">2</xref> Even though few cases of serious interactions occur, the suspected iatrogenic risks must be considered and controlled.<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref> Accordingly, an important percentage of hospital admissions caused by medication can be attributed to drug interactions.<xref rid="B6" ref-type="bibr">6</xref>-<xref rid="B11" ref-type="bibr">11</xref></p><p>The European Council&#x02019;s resolution about the pharmacist&#x02019;s role within the health security framework establishes that verifying the appropriateness in the prescription and the possible interactions is a desirable practice.<xref rid="B12" ref-type="bibr">12</xref> In this context, the community pharmacy is in a privileged position to detect these phenomena because medical prescriptions from different physicians, dental prescriptions, and self-medication converge in the pharmacy.<xref rid="B13" ref-type="bibr">13</xref> In Spain, one study<xref rid="B14" ref-type="bibr">14</xref> shows that only 6% of pharmacies detected a relevant drug-drug interaction, while studies undertaken in the USA<xref rid="B15" ref-type="bibr">15</xref> present higher values (32%).</p><p>Most pharmacies in Spain are computerized. Pharmacy management software includes a Consejo General de Colegios Oficiales de Farmac&#x000e9;uticos (CGCOF) database that allows the automatic detection of potential DDIs between dispensed drugs. Although useful, the low specificity of drug interaction detection means that the attention paid to the alerts issued by these computer systems is lost.<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref> Systematically overriding potential DDIs via configuring the alert systems can be distinguished from overriding potential DDIs generated by computer alerts without further action.<xref rid="B18" ref-type="bibr">18</xref></p><p>The identification of a potential DDI does not necessarily lead to a negative outcome, as it involves characteristics of the patient, the drugs, and the use of the drugs.<xref rid="B19" ref-type="bibr">19</xref> Several works have studied drug interactions and have also analyzed them according to clinical relevance.<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref></p><p>We analyzed the prevalence of potential DDIs detected in community pharmacies during dispensing and the relationship with negative clinical outcomes.</p></sec><sec sec-type="methods" id="S2"><title>METHODS</title><p>The potential DDIs in connection with negative clinical outcomes were analyzed in two community pharmacies in the province of Alicante (Spain), one located in Aspe (inland) and the other based in El Campello (coastal). Both pharmacies had similar characteristics in terms of personnel and the origin of prescriptions. The study was carried out over a six-month period from June to December, 2005.</p><p>The dispensing operations data were registered according to two groups. One group (the study group) was formed by dispensing operations in which a potential DDI was detected. The second group (the comparison group) included randomized dispensing operations in which no potential DDI was detected.</p><p>Dispensing was done using commercial management software that included the CGCOF database (Spanish Pharmacists Association). This software produces an alert for potential drug interactions. The pharmacist was called by the technician when a potential DDI alert appeared. Then, the pharmacist completed the process. Potential DDIs detected by the pharmacist that were not included in this database were also registered.</p><p>All negative outcomes were classified according to the Third Consensus of Granada on Drug-related Problems and Negative Outcomes Associated with Medication.<xref rid="B20" ref-type="bibr">20</xref></p><p>In the study group, we acted in accordance with a decision algorithm after detecting a potential DDI (<xref ref-type="fig" rid="F1">Figure 1</xref>). The first criterion used in this protocol was to look at the likelihood of seeing the negative clinical outcome. The drug administration route was considered, as were the doses, and whether it involved a novel drug or they had been taken together for a long time. The case was recorded if it was considered that no negative outcome would appear.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Decision algorithm after detecting an interaction</p></caption><graphic xlink:href="pharmpract-07-034-g001"/></fig><p>If there was a possibility that a negative clinical outcome would appear, we then asked the patient for possible clinical signs and symptoms. If no sign was detected, when considered relevant we informed the patient to return to the community pharmacy should these signs ever appear. Conversely, when negative clinical outcome signs were detected, we offered the patient pharmacotherapy follow-up.</p><p>If a serious potential DDI was detected (defined as that which would likely require an urgent change in therapy), dispensing was suspended according to the information taken from the patient. This information had to fit at least one of two assumptions: that the physician did not know the use of all the drugs involved, and that it was the first time that the patient used one of the drugs. In both cases the patient was advised to refer back to his/her physician, and the case was excluded.</p><p>The following data were registered in the study group: the potential DDI; the patient&#x02019;s name, age, and gender; the drugs involved and whether these drugs were prescribed; the possible negative clinical outcome; the detection of a drug-related negative clinical outcome; and any information given either to the patient or physician. In the comparison group, age and gender were also registered and expressed as the mean value and standard error (SE). The ages of both groups were compared using the Student&#x02019;s t-test. Gender differences were evaluated between the two groups using the chi-square test. The level of statistical relevance used in both analyses was p&#x0003c;0.05. The rest of the data are expressed as the mean value and standard deviation (SD).</p></sec><sec id="S3"><title>RESULTS</title><p>During this study, 39,340 dispensing operations were performed, and 417 potential DDIs were detected (1.06% of dispenses lead to a potential DDI). These 417 potential DDIs were detected in 318 dispensing operations (see <xref ref-type="table" rid="T1">Table 1</xref>). The mean rate of the potential DDIs per dispensing was 1.31 (SD=0.72 range 1 to 5). Only one (n=254 dispensing acts; 79.9%) or two (n=43 dispensing acts; 13.5%) potential DDIs were detected in the majority of cases. However, there were cases of three (n=11; 3.4%), four (n=7; 2.3%), and five (n=3 dispensing acts; 0.9%) potential DDIs registered for the same dispensing act.</p><table-wrap orientation="portrait" id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of study and control groups.</p></caption><table frame="hsides" rules="groups"><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Potential DDI group</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1">p value</th></tr><tr><td align="left" rowspan="1" colspan="1">Number of potential DDIs detected</td><td align="center" rowspan="1" colspan="1">417</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of dispensing operations</td><td align="center" rowspan="1" colspan="1">318</td><td align="center" rowspan="1" colspan="1">417</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)&#x000b1;SE</td><td align="center" rowspan="1" colspan="1">59.8&#x000b1;0.9</td><td align="center" rowspan="1" colspan="1">51.3&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">p&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1">204 women 114 men</td><td align="center" rowspan="1" colspan="1">233 women 184 men</td><td align="center" rowspan="1" colspan="1">p&#x0003c;0.050</td></tr></table></table-wrap><p>The mean age of patients with potential DDIs was 59.8 (SE=0.9) years old, and it was 51.3 (SE=1.1) years old for dispensing without potential DDIs (p&#x0003c;0.001). Gender registration data were also significantly different between both groups, with a high rate of women in the potential DDI group (204 women of 318 dispensing acts vs. 233 women of 417 dispensing acts in the comparison group; p&#x0003c;0.05).</p><p>Pharmacists found 10 (2.4%) potential DDIs not appearing in the computerized alert system, despite being described in either the literature, the summary of product characteristics of the drugs involved, or in the drug description in the database.</p><p>Active substances and excipients involved in the vast majority of potential DDI cases appear in <xref ref-type="table" rid="T2">Table 2</xref>. The most frequently detected potential DDIs are presented in <xref ref-type="table" rid="T3">Table 3</xref>.</p><table-wrap orientation="portrait" id="T2" position="float"><label>Table 2</label><caption><p>Main drugs or excipients involved in potential DDIs.</p></caption><table frame="hsides" rules="groups"><tr><th align="center" rowspan="1" colspan="1">Drug or excipient</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr><tr><td align="left" rowspan="1" colspan="1">Acenocoumarol</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">8.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium salts</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">6.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydrochlorothiazide</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">4.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Alendronic acid</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">4.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Metformin</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">4.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Omeprazol</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">3.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Paracetamol</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">3.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Digoxin</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">2.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Sucrose</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">2.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Glibenclamide</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">2.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Simvastatin</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Amiodarone</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">2.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">2.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Ibuprofen</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Propranolol</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Risendronic Acid</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">1.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Acetylsalicylic acid</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Carbamazepine</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Clorazepate</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Enalapril</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Espironolactone</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Allopurinol</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Atenolol</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Captopril</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Furosemide</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Torasemide</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Metrotexate</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">286</td><td align="center" rowspan="1" colspan="1">34</td></tr></table></table-wrap><table-wrap orientation="portrait" id="T3" position="float"><label>Table 3</label><caption><p>Main potential DDIs detected and potential adverse effect associated.</p></caption><table frame="hsides" rules="groups"><tr><th align="center" rowspan="1" colspan="1">Potential DDI</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Potential adverse effect</th></tr><tr><td align="left" rowspan="1" colspan="1">Calcium salts + bisphosphonates</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">8.9</td><td align="center" rowspan="1" colspan="1">Decreased bisphosphonate effectiveness</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral antidiabetic + thiazide diuretics</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">Decreased antidiabetic effectiveness</td></tr><tr><td align="left" rowspan="1" colspan="1">Antidiabetic + glucose</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">Decreased antidiabetic effectiveness</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral anticoagulant + paracetamol</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">4.3</td><td align="center" rowspan="1" colspan="1">Hemorrhage risk</td></tr><tr><td align="left" rowspan="1" colspan="1">Antidiabetic + ACE Inhibitors</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">4.1</td><td align="center" rowspan="1" colspan="1">Hypoglycaemia</td></tr><tr><td align="left" rowspan="1" colspan="1">Benzodiazepines + omeprazol</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">3.4</td><td align="center" rowspan="1" colspan="1">Benzodiazepine intoxication risk</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral anticoagulant + HMG-CoA Reductase Inhibitors</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">Hemorrhage risk</td></tr><tr><td align="left" rowspan="1" colspan="1">Antidiabetic + beta blockers</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">Decreased diabetic control</td></tr><tr><td align="left" rowspan="1" colspan="1">Amiodarone + statins</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">Statin intoxication risk</td></tr><tr><td align="left" rowspan="1" colspan="1">Antitussive + mucoltycs</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">Risk of stasis of the fluid snot</td></tr><tr><td align="left" rowspan="1" colspan="1">Alendronic acid + NSAID</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">Risk of gastric sore</td></tr><tr><td align="left" rowspan="1" colspan="1">Potassium-sparing diuretics + ACE Inhibitors</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">1.7</td><td align="center" rowspan="1" colspan="1">Risk of hyperkalemia</td></tr><tr><td align="left" rowspan="1" colspan="1">Paracetamol + oral contraceptive</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">Decreased paracetamol effectiveness</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral anticoagulant + amiodarone</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">Hemorrhage risk</td></tr><tr><td align="left" rowspan="1" colspan="1">Digitalic + Potassium-sparing diuretics</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">Risk of digitalic intoxication</td></tr><tr><td align="left" rowspan="1" colspan="1">Salicylate + antiacid</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">Decreased salicylate effectiveness</td></tr><tr><td align="left" rowspan="1" colspan="1">Thiazide diuretic + alopurinol</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">Risk of allergic reactions</td></tr><tr><td align="left" rowspan="1" colspan="1">Loop diuretics + NSAID</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">Decreased diuretic and antihipertensive effectiveness</td></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1">195</td><td align="center" rowspan="1" colspan="1">46.8</td><td rowspan="1" colspan="1"/></tr></table></table-wrap><p>In 21 (5%) potential DDIs, a dispensed drug that was not prescribed by a physician but could be obtained over the counter was detected.</p><p>Only 4 (0.96%) potential DDIs led to a negative clinical outcome (50% safety and 50% effectiveness cases). These negative outcomes involved NSAIDs in two cases and benzodiazepines in another two; 22% and 9% of the potential DDIs with NSAID and benzodiazepine, respectively, led to a negative clinical outcome.</p><p>In 23.2% of the detected potential DDI cases, the patient was directly informed about the drug interaction. This information was given to the physician in only 1% of cases.</p></sec><sec id="S4"><title>DISCUSSION</title><p>We tested potential DDIs in connection with negative clinical outcomes in two Spanish community pharmacies. NSAIDs or benzodiazepines appeared in all potential DDIs that had negative clinical outcomes, suggesting acting with caution in potential DDIs where these drugs appear.</p><p>The frequency of potential DDIs in dispensing (1.06%) is generally lower than other studies, with prevalence from 0.8 to 80%.<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B21" ref-type="bibr">21</xref>-<xref rid="B23" ref-type="bibr">23</xref> However, different methodologies, the potential DDIs considered, the study population, the year of the study, and inclusion of non-prescription drugs can all affect these values. For example, we only considered medications identified during a specific dispensing, and did not consider the patient&#x02019;s medication history. DDIs must be identified to be prevented, and experience (measured as years of pharmacy training) improved the accuracy identifying potential DDIs.<xref rid="B24" ref-type="bibr">24</xref> Alert systems are also effective in community pharmacies and in physician offices in reducing the number of potential DDIs.<xref rid="B25" ref-type="bibr">25</xref> Nevertheless, these systems are not a panacea<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B26" ref-type="bibr">26</xref>, and require optimization of alerts<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B26" ref-type="bibr">26</xref> and access to complete medication history.</p><p>The age of patients with potential DDIs was significantly higher than the group where no potential DDI was detected, consistent with other studies where the number of potential DDIs increased with the patient age<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B27" ref-type="bibr">27</xref>, as do the number of drugs used.<xref rid="B27" ref-type="bibr">27</xref> We also found a higher proportion of women in the group with potential DDIs. Other studies found similar gender-related differences, suggesting that perhaps women take more medication than men, and also live longer.<xref rid="B28" ref-type="bibr">28</xref> Importantly, the most frequent interaction found, bisphosphonate and calcium salts, is generally used to treat osteoporosis in postmenopausal women.</p><p>The average number of potential DDIs per patient of 1.31 (SD=0.72) was similar to that described by other authors in ambulatory patients<xref rid="B29" ref-type="bibr">29</xref>, but was slightly lower than in hospitalized patients.<xref rid="B30" ref-type="bibr">30</xref> In this sense, Kohler et al.<xref rid="B31" ref-type="bibr">31</xref> found that the number of interactions per patient was higher during hospitalization than prior to it.</p><p>Drugs usually involved in potential DDIs included some drugs frequently used in primary care, such as omeprazole or paracetamol. Other potential DDIs involved drugs that are normally used together, like calcium salts and alendronic acid. This could cause overlap in findings of other studies. For example, of the 24 drugs that caused 60% of potential DDIs, only 6 in this study were not indicated among the drugs that caused 84% of potential DDIs in Barris et al.<xref rid="B19" ref-type="bibr">19</xref></p><p>In 5% of potential DDI cases, one of the drugs did not require a prescription. Strong control of potential DDIs involves the pharmacist because they might be the only health worker to evaluate the risks. In the work of Barris et al.<xref rid="B19" ref-type="bibr">19</xref>, these potential DDIs constituted one of the main causes of pharmaceutical intervention. These facts show the importance of a specific pharmaceutical indication and/or active dispensing of medication without a prescription.</p><p>The common potential DDIs in this study were similar to the potential DDIs found by other authors.<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B22" ref-type="bibr">22</xref></p><p>In this study, the pharmacists detected that 0.94% of the potential DDIs led to a negative outcome in pharmacotherapy. Potential DDIs are a source of adverse drug events.<xref rid="B7" ref-type="bibr">7</xref>-<xref rid="B11" ref-type="bibr">11</xref> NSAIDs and benzodiazepines were both involved in two drug-related negative clinical outcomes. A considerable percentage of potential DDIs with NSAID and benzodiazepine (22% and 9%, respectively) led to a negative clinical outcome. Therefore, tighter control of such cases is recommended. NSAIDs are more involved in clinically relevant pharmacological interactions.<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B11" ref-type="bibr">11</xref></p><p>Of the interactions with a negative clinical outcome, zolpidem and diazepam did not appear in the CGCOF database, although this interaction appeared in the Summary of Product Characteristics of Stilnox (zolpidem). Nine other potential DDIs were not registered in the CGCOF database. Abarca et al.<xref rid="B26" ref-type="bibr">26</xref> suggested that the performance of community pharmacy computer systems in screening potential DDIs has improved. Nevertheless, many pharmacy computer systems may be operating at low levels of sensitivity and specificity when screening for DDIs. Databases often have significant omissions and should be dynamically updated.<xref rid="B32" ref-type="bibr">32</xref> Moreover, one of the ten non-registered potential DDIs led to a negative outcome, indicating the importance of both the database alerts and other combinations of drugs that may cause a potential DDI, such as combining drugs with similar or opposite effects.</p><p>Some of the drug-related negative clinical outcomes were probably not detected because six patients declined the offer of pharmacotherapy follow-up. Moreover, not detecting a sign when questioning patients does not exclude the possibility of a negative outcome associated with medication. We also only considered drugs identified during dispensing, but patients are probably exposed to a higher number of potential DDIs that could produce negative outcomes.</p></sec><sec id="S5"><title>CONCLUSIONS</title><p>In our study, the majority of potential drug interactions have no clinical relevance, but a small proportion (0.96%) lead to negative outcomes. These negative clinical outcomes suggest acting with caution in potential DDIs where NSAIDs or benzodiazepines appear.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>The authors thank Diego Echevarria, Ph.D. and Juan Miragall, M.Sc. for their critical reading of the manuscript.</p></ack><fn-group><fn fn-type="conflict"><p><bold>CONFLICT OF INTEREST</bold></p><p>None declared.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlo</surname><given-names>J</given-names></name><name><surname>Liedholm</surname><given-names>H</given-names></name><name><surname>Lindblad</surname><given-names>U</given-names></name><name><surname>Bjorck-Linne</surname><given-names>A</given-names></name><name><surname>Falt</surname><given-names>J</given-names></name><name><surname>Lindberg</surname><given-names>G</given-names></name><name><surname>Melander</surname><given-names>A</given-names></name></person-group><article-title>Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study</article-title><source>BMJ</source><year>2001</year><volume>323</volume><issue>7310</issue><fpage>427</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">11520839</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stokley</surname><given-names>IH</given-names></name></person-group><article-title>Interacciones farmacol&#x000f3;gicas</article-title><year>2004</year><publisher-loc>Barcelona</publisher-loc><publisher-name>Pharma Editores</publisher-name></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvet</surname><given-names>A</given-names></name><name><surname>D&#x000ed;ez de Ulzurrum</surname></name><name><surname>P&#x000e9;rez</surname><given-names>MT</given-names></name><name><surname>Esteras</surname><given-names>J</given-names></name></person-group><article-title>Interacciones farmacol&#x000f3;gicas en tratamientos cr&#x000f3;nicos: medidas correctoras para su prevenci&#x000f3;n en un &#x000e1;rea b&#x000e1;sica de salud</article-title><source>Aten Primaria</source><year>2001</year><volume>27</volume><issue>1</issue><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">11218973</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>CC</given-names></name><name><surname>Glassman</surname><given-names>PA</given-names></name><name><surname>Marks</surname><given-names>IR</given-names></name><name><surname>Powler</surname><given-names>C</given-names></name><name><surname>Castiglione</surname><given-names>B</given-names></name><name><surname>Good</surname><given-names>CB</given-names></name></person-group><article-title>Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population</article-title><source>J Manag Care Pharm</source><year>2003</year><volume>9</volume><issue>6</issue><fpage>513</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">14664659</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>ML</given-names></name><name><surname>Kallewaard</surname><given-names>M</given-names></name><name><surname>Caspers</surname><given-names>PW</given-names></name><name><surname>Schalekamp</surname><given-names>T</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name></person-group><article-title>Potential determinants of drug-drug interaction associated dispensing in community pharmacies</article-title><source>Drug Saf</source><year>2005</year><volume>28</volume><issue>5</issue><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">15853439</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manchon</surname><given-names>ND</given-names></name><name><surname>Bercoff</surname><given-names>E</given-names></name><name><surname>Lemarchand</surname><given-names>P</given-names></name><name><surname>Chassagne</surname><given-names>P</given-names></name><name><surname>Senant</surname><given-names>J</given-names></name><name><surname>Bourreille</surname><given-names>J</given-names></name></person-group><article-title>Incidence and severity of drug interactions in the elderly: a prospective study of 639 patients</article-title><source>Rev Med Interne</source><year>1989</year><volume>10</volume><issue>6</issue><fpage>521</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">2488503</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huic</surname><given-names>M</given-names></name><name><surname>Mucolic</surname><given-names>V</given-names></name><name><surname>Vrhovac</surname><given-names>B</given-names></name><name><surname>Francetic</surname><given-names>I</given-names></name><name><surname>Bakran</surname><given-names>I</given-names></name><name><surname>Giljanovic</surname><given-names>S</given-names></name></person-group><article-title>Adverse drug reactions resulting in hospital admission</article-title><source>Int J Clin Pharmacol Ther</source><year>1994</year><volume>32</volume><issue>12</issue><fpage>675</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">7881707</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonnell</surname><given-names>PJ</given-names></name><name><surname>Jacobs</surname><given-names>MR</given-names></name></person-group><article-title>Hospital admissions resulting from preventable adverse drug reactions</article-title><source>Ann Pharmacother</source><year>2002</year><volume>36</volume><issue>9</issue><fpage>1331</fpage><lpage>1336</lpage><pub-id pub-id-type="pmid">12196047</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juurlink</surname><given-names>DN</given-names></name><name><surname>Mamdani</surname><given-names>M</given-names></name><name><surname>Kopp</surname><given-names>A</given-names></name><name><surname>Laupacis</surname><given-names>A</given-names></name><name><surname>Redelmeier</surname><given-names>DA</given-names></name></person-group><article-title>Drug-drug interactions among elderly patients hospitalized for drug toxicity</article-title><source>JAMA</source><year>2003</year><volume>289</volume><issue>13</issue><fpage>1652</fpage><lpage>1654</lpage><pub-id pub-id-type="pmid">12672733</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandson</surname><given-names>N</given-names></name></person-group><article-title>Drug-drug interactions: The silent epidemic</article-title><source>Psychiat Serv</source><year>2005</year><volume>56</volume><issue>1</issue><fpage>22</fpage><lpage>24</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>ML</given-names></name><name><surname>Kallewaard</surname><given-names>M</given-names></name><name><surname>Caspers</surname><given-names>PW</given-names></name><name><surname>Visser</surname><given-names>LE</given-names></name><name><surname>Leufkens</surname><given-names>HG</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name></person-group><article-title>Hospitalisations and emergency department visits due to drug-drug interactions: a literature review</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2007</year><volume>16</volume><issue>6</issue><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">17154346</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><article-title>Resoluci&#x000f3;n ResAP (2001) 2 sobre el papel de los farmac&#x000e9;uticos en el marco de la seguridad sanitaria</article-title><source>Consejo de Europa</source></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lien</surname><given-names>LL</given-names></name><name><surname>Lien</surname><given-names>EJ</given-names></name></person-group><article-title>Preventing potential drug interactions in community pharmacie</article-title><source>J Clin Pharm Ther</source><year>1994</year><volume>19</volume><issue>6</issue><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">7876369</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acosta</surname><given-names>J</given-names></name><name><surname>Alzaga</surname><given-names>A</given-names></name><name><surname>&#x000c1;lvarez</surname><given-names>L</given-names></name><name><surname>Gudiel</surname><given-names>M</given-names></name><name><surname>Fern&#x000e1;ndez-Llimos</surname><given-names>F</given-names></name></person-group><article-title>An&#x000e1;lisis del proceso de dispensaci&#x000f3;n y detecci&#x000f3;n de interacci&#x000f3;n potencial en farmacias de Alcorc&#x000f3;n (Madrid) y Bilbao</article-title><source>Seguim Farmacoter</source><year>2004</year><volume>2</volume><issue>1</issue><fpage>32</fpage><lpage>36</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavuto</surname><given-names>NJ</given-names></name><name><surname>Woosley</surname><given-names>RL</given-names></name><name><surname>Sale</surname><given-names>M</given-names></name></person-group><article-title>Pharmacies and prevention of potentially fatal drug interactions</article-title><source>JAMA</source><year>1996</year><volume>275</volume><issue>14</issue><fpage>1086</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">8601923</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westein</surname><given-names>MP</given-names></name><name><surname>Herings</surname><given-names>RM</given-names></name><name><surname>Leufkens</surname><given-names>HG</given-names></name></person-group><article-title>Determinants of pharmacist&#x000b4;s interventions linked to prescription processing</article-title><source>Pharm World Sci</source><year>2001</year><volume>23</volume><issue>3</issue><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">11468883</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glassman</surname><given-names>PA</given-names></name><name><surname>Simon</surname><given-names>B</given-names></name><name><surname>Belperio</surname><given-names>P</given-names></name><name><surname>Lanto</surname><given-names>A</given-names></name></person-group><article-title>Improving recognition of drug interactions: benefits and barriers to using automated drug alerts</article-title><source>Med Care</source><year>2002</year><volume>40</volume><issue>12</issue><fpage>1161</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">12458299</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Indermitte</surname><given-names>J</given-names></name><name><surname>Beutler</surname><given-names>M</given-names></name><name><surname>Bruppacher</surname><given-names>R</given-names></name><name><surname>Meier</surname><given-names>CR</given-names></name><name><surname>Hersberger</surname><given-names>KE</given-names></name></person-group><article-title>Management of drug-interaction alerts in community pharmacies</article-title><source>J Clin Pharm Ther</source><year>2007</year><volume>32</volume><issue>2</issue><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">17381663</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barris</surname><given-names>D</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>C</given-names></name><name><surname>Sabio</surname><given-names>B</given-names></name><name><surname>Garrido</surname><given-names>B</given-names></name></person-group><article-title>Interacciones farmacol&#x000f3;gicas detectadas en una farmacia comunitaria</article-title><source>Pharm Care Esp</source><year>2003</year><volume>5</volume><fpage>261</fpage><lpage>267</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><collab>Consensus Committee</collab><article-title>Third Consensus of Granada in Drug Related Problems (DRP) and Negative Outcomes associated with Medication (NOM)</article-title><source>Ars Pharm</source><year>2007</year><volume>48</volume><issue>1</issue><fpage>5</fpage><lpage>17</lpage></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linnarsson</surname><given-names>R</given-names></name></person-group><article-title>Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system</article-title><source>Scand J Prim Health Care</source><year>1993</year><volume>11</volume><issue>3</issue><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">8272649</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doubova</surname><given-names>Dubova SV</given-names></name><name><surname>Reyes-Morales</surname><given-names>H</given-names></name><name><surname>Torres-Arreola</surname><given-names>Ldel P</given-names></name><name><surname>Su&#x000e1;rez-Ortega</surname></name></person-group><article-title>Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City</article-title><source>BMC Health Serv Res</source><year>2007</year><volume>7</volume><fpage>147</fpage><pub-id pub-id-type="pmid">17880689</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmood</surname><given-names>M</given-names></name><name><surname>Malone</surname><given-names>DC</given-names></name><name><surname>Skrepnek</surname><given-names>GH</given-names></name><name><surname>Abarca</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>EP</given-names></name><name><surname>Murphy</surname><given-names>JE</given-names></name><name><surname>Grizzle</surname><given-names>AJ</given-names></name><name><surname>Ko</surname><given-names>Y</given-names></name><name><surname>Woosley</surname><given-names>RL</given-names></name></person-group><article-title>Potential drug-drug interactions within Veterans Affairs medical centers</article-title><source>Am J Health Syst Pharm</source><year>2007</year><volume>64</volume><issue>14</issue><fpage>1500</fpage><lpage>1505</lpage><pub-id pub-id-type="pmid">17617500</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weideman</surname><given-names>RA</given-names></name><name><surname>Bernstein</surname><given-names>IH</given-names></name><name><surname>McKinney</surname><given-names>WP</given-names></name></person-group><article-title>Pharmacist recognition of potential drug interactions</article-title><source>Am J Health Syst Pharm</source><year>1999</year><volume>56</volume><issue>15</issue><fpage>1524</fpage><lpage>1529</lpage><pub-id pub-id-type="pmid">10478990</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halkin</surname><given-names>H</given-names></name><name><surname>Katzir</surname><given-names>I</given-names></name><name><surname>Kurman</surname><given-names>I</given-names></name><name><surname>Jan</surname><given-names>J</given-names></name><name><surname>Malkin</surname><given-names>BB</given-names></name></person-group><article-title>Preventing drug interactions by online prescription screening in communitypharmacies and medical practices</article-title><source>Clin Pharmacol Ther</source><year>2001</year><volume>69</volume><issue>4</issue><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">11309555</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abarca</surname><given-names>J</given-names></name><name><surname>Colon</surname><given-names>LR</given-names></name><name><surname>Wang</surname><given-names>VS</given-names></name><name><surname>Malone</surname><given-names>DC</given-names></name><name><surname>Murphy</surname><given-names>JE</given-names></name><name><surname>Armstrong</surname><given-names>EP</given-names></name></person-group><article-title>Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies</article-title><source>J Manag Care Pharm</source><year>2006</year><volume>12</volume><issue>5</issue><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">16792445</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>SS</given-names></name><name><surname>R&#x000e4;tz</surname><given-names>Bravo AE</given-names></name><name><surname>Hess</surname><given-names>L</given-names></name><name><surname>Schlienger</surname><given-names>RG</given-names></name><name><surname>Kr&#x000e4;henb&#x000fc;hl</surname><given-names>S</given-names></name></person-group><article-title>Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins</article-title><source>Drugs Aging</source><year>2007</year><volume>24</volume><issue>5</issue><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">17503898</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malone</surname><given-names>DC</given-names></name><name><surname>Hutchins</surname><given-names>DS</given-names></name><name><surname>Haupert</surname><given-names>H</given-names></name><name><surname>Hansten</surname><given-names>P</given-names></name><name><surname>Duncan</surname><given-names>B</given-names></name><name><surname>Van Bergen</surname><given-names>RC</given-names></name><name><surname>Solomon</surname><given-names>SL</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group><article-title>Assessment of potential drug-drug interactions with a prescription claims database</article-title><source>Am J Health Syst Pharm</source><year>2005</year><volume>62</volume><issue>19</issue><fpage>1983</fpage><lpage>1991</lpage><pub-id pub-id-type="pmid">16174833</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Kukulka</surname><given-names>G</given-names></name></person-group><article-title>Frequency of Drug Interactions Among Primary Care Patients at a Family Medicine Residency Clinic</article-title><source>Abstracts 2006 NAPCRG Annual Meeting PS184</source></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez</surname><given-names>V&#x000e1;zquez P</given-names></name><name><surname>Rodriguez</surname><given-names>Moreno C</given-names></name><name><surname>Duran</surname><given-names>Parrondo C</given-names></name><name><surname>Tato</surname><given-names>Herrero F</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>L&#x000f3;pez I</given-names></name><name><surname>Lado</surname><given-names>Lado FL</given-names></name></person-group><article-title>Interacciones entre medicamentos prescritos al alta en un servicio de medicina interna</article-title><source>An Med Interna</source><year>2005</year><volume>22</volume><issue>2</issue><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">15898883</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname><given-names>GI</given-names></name><name><surname>Bode-Boger</surname><given-names>SM</given-names></name><name><surname>Busse</surname><given-names>R</given-names></name><name><surname>Hoopmann</surname><given-names>M</given-names></name><name><surname>Welte</surname><given-names>T</given-names></name><name><surname>Boger</surname><given-names>RH</given-names></name></person-group><article-title>Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use</article-title><source>Int J Clin Pharmacol Ther</source><year>2000</year><volume>38</volume><issue>11</issue><fpage>504</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">11097142</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Diego</surname><given-names>A</given-names></name><name><surname>Alvarellos</surname><given-names>ML</given-names></name><name><surname>Del Barrio</surname><given-names>H</given-names></name></person-group><article-title>An&#x000e1;lisis de la compleci&#x000f3;n de la base de datos del Consejo General de Colegios Oficiales de Farmac&#x000e9;uticos sobre interacciones entre medicamentos</article-title><source>Pharm Care Esp</source><year>1999</year><volume>1</volume><fpage>184</fpage><lpage>193</lpage></element-citation></ref></ref-list></back></article>